DE69027989D1 - Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON - Google Patents

Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON

Info

Publication number
DE69027989D1
DE69027989D1 DE69027989T DE69027989T DE69027989D1 DE 69027989 D1 DE69027989 D1 DE 69027989D1 DE 69027989 T DE69027989 T DE 69027989T DE 69027989 T DE69027989 T DE 69027989T DE 69027989 D1 DE69027989 D1 DE 69027989D1
Authority
DE
Germany
Prior art keywords
remains
modified
chemical modifications
cavs
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69027989T
Other languages
English (en)
Other versions
DE69027989T2 (de
Inventor
Gray Shaw
Geertruida Veldman
Joseph Wooters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE69027989D1 publication Critical patent/DE69027989D1/de
Publication of DE69027989T2 publication Critical patent/DE69027989T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69027989T 1989-04-21 1990-04-19 Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON Expired - Fee Related DE69027989T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/341,990 US5166322A (en) 1989-04-21 1989-04-21 Cysteine added variants of interleukin-3 and chemical modifications thereof
PCT/US1990/002144 WO1990012874A2 (en) 1989-04-21 1990-04-19 Cysteine added variants of polypeptides and chemical modifications thereof

Publications (2)

Publication Number Publication Date
DE69027989D1 true DE69027989D1 (de) 1996-09-05
DE69027989T2 DE69027989T2 (de) 1997-02-20

Family

ID=23339864

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027989T Expired - Fee Related DE69027989T2 (de) 1989-04-21 1990-04-19 Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON

Country Status (9)

Country Link
US (1) US5166322A (de)
EP (3) EP0668353A1 (de)
JP (1) JP2557144B2 (de)
AT (1) ATE140969T1 (de)
AU (1) AU5553790A (de)
DE (1) DE69027989T2 (de)
DK (1) DK0469074T3 (de)
ES (1) ES2090132T3 (de)
WO (1) WO1990012874A2 (de)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
JPH05271279A (ja) * 1991-08-07 1993-10-19 Takeda Chem Ind Ltd ヒト副甲状腺ホルモンムテインおよびその製造法
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
WO1993012142A1 (en) * 1991-12-10 1993-06-24 Tanox Biosystems, Inc. Cytokines with an unpaired cysteine residue and conjugates thereof
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5705362A (en) * 1992-05-25 1998-01-06 Gist-Brocades, N.V. Modified signal sequences
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
ES2211875T3 (es) * 1992-11-24 2004-07-16 G.D. SEARLE & CO. Polipeptidos mutantes de interleuquina 3 (il-3).
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
WO1994013316A1 (en) * 1992-12-16 1994-06-23 Board Of Regents, The University Of Texas System Potent and specific chemically-conjugated immunotoxins
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
CA2176115A1 (en) * 1993-11-10 1995-05-18 Clifford M. Snapper Compositions and method for stimulating antibody release by b lymphocytes
WO1995016035A2 (en) 1993-12-07 1995-06-15 Genetics Institute, Inc. Bmp-12, bmp-13 and tendon-inducing compositions thereof
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1995032003A1 (en) * 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
EP0785276A4 (de) * 1994-09-29 2002-01-09 Ajinomoto Kk Modifizierung eines peptids und eines proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US5747027A (en) * 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
JP2863638B2 (ja) * 1996-01-26 1999-03-03 ベーリンガー マンハイム コーポレイション ビスーマレイミド架橋剤
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4410852B2 (ja) * 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
BR9606270A (pt) * 1996-12-18 1998-09-22 Univ Minas Gerais Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
US6870033B1 (en) 1997-02-21 2005-03-22 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
BR9812267B1 (pt) * 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
EP1003539A4 (de) 1997-08-14 2002-09-11 Univ California FLUORESZIERENDE AMYLOID A beta PEPTIDE UND DEREN VERWENDUNG
AU763719B2 (en) 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
CZ298579B6 (cs) 1998-04-28 2007-11-14 Applied Research Systems Ars Holding N. V. Konjugát polyolu a interferonu-beta
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
LT2599503T (lt) * 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1144613B2 (de) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Verfahren zur herstellung von proteinen mit freien cysteinresten
EA004685B1 (ru) * 1999-01-29 2004-06-24 Эмджен Инк. Конъюгаты гксф
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU5805500A (en) * 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4703926B2 (ja) 1999-10-15 2011-06-15 ジェネティクス インスティテュート，エルエルシー 骨形成蛋白をデリバリーするためのヒアルロン酸の処方
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2001259785A1 (en) 2000-05-15 2001-11-26 Tecan Trading Ag Microfluidics devices and methods for performing cell based assays
JP4873818B2 (ja) * 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
EP1336410A4 (de) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd Protein-injektionszubereitungen
AU2001277781A1 (en) 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
AU2001282607B2 (en) 2000-09-01 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001273388B2 (en) * 2000-09-08 2005-01-13 Gryphon Therapeutics, Inc. "Pseudo"-native chemical ligation
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
EP2336149A1 (de) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Methode zur Proteinaufreinigung
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7531358B2 (en) 2001-04-17 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Method of quantifying surfactant
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
JP2002346015A (ja) * 2001-05-28 2002-12-03 Hiroaki Yoshiike スイング診断装置
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CN1596304A (zh) * 2001-11-08 2005-03-16 威廉R·莫伊尔 蛋白质结节
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2003055526A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
AU2003210052A1 (en) * 2002-03-20 2003-09-29 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
HUE027134T2 (en) 2002-09-11 2016-10-28 Chugai Pharmaceutical Co Ltd Method for protein purification
US20060177894A1 (en) * 2002-11-08 2006-08-10 Moyle William R Protein knobs
RU2366664C2 (ru) 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP4490290B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
KR100512483B1 (ko) * 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
SI1629007T1 (sl) 2003-05-12 2009-10-31 Affymax Inc Novi peptidi, ki se veĹľejo na eritropoetinski receptor
WO2004101611A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
EP1628686A2 (de) 2003-05-12 2006-03-01 Affymax, Inc. Abstandsteil für mit poly (ethylenglycol) modifizierten peptide
EP1626983B8 (de) 2003-05-12 2010-12-22 Affymax, Inc. Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP4808157B2 (ja) * 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CA2539033C (en) * 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
EP1675608B1 (de) 2003-09-12 2007-03-21 Wyeth Injizierbare feste calciumphosphat-stäbe zur abgabe von osteogenen proteinen
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004297228A1 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
KR101100059B1 (ko) 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005286763A1 (en) * 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
KR101654011B1 (ko) 2004-11-12 2016-09-05 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1848461A2 (de) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Konjugate einer epo-gruppierung und eines polymers
CN100381420C (zh) * 2005-03-23 2008-04-16 于勇海 一种n-乙酰基半胱氨酸衍生物与应用
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
EP1893632B1 (de) * 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
DE602006013151D1 (de) 2005-07-19 2010-05-06 Nektar Therapeutics Verfahren zur herstellung von polymermaleimiden
KR20080033439A (ko) * 2005-08-04 2008-04-16 넥타르 테라퓨틱스 에이엘, 코포레이션 Ｇ-ｃｓｆ 부분 및 중합체의 컨주게이트
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007041614A2 (en) * 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
BRPI0712008A2 (pt) * 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
JP5723528B2 (ja) 2006-08-04 2015-05-27 プロロング ファーマシューティカルズ エルエルシー 修飾されたエリスロポエチン
WO2008023725A1 (fr) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Agent préventif et/ou thérapeutique pour une neuropathie périphérique
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
EP2102355B1 (de) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
EP2118127A4 (de) 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP2185689A2 (de) 2007-08-09 2010-05-19 Genzyme Corporation Verfahren zur behandlung von autoimmunerkrankungen mit mesenchymalen stammzellen
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
PL2195338T3 (pl) 2007-10-01 2014-05-30 Pharmaessentia Corp Interferon alfa zmodyfikowany na końcu N
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
IL295201A (en) 2010-11-12 2022-10-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
NZ717668A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017096311A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
CN111093688A (zh) 2017-05-15 2020-05-01 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
US20230158141A1 (en) * 2017-11-08 2023-05-25 Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd Conjugates of Biomolecule and Use Thereof
US11732016B2 (en) 2017-12-27 2023-08-22 Council Of Scientific & Industrial Research Polypeptide exhibiting granulocyte-colony stimulating factor activity
JPWO2019225568A1 (ja) 2018-05-21 2021-07-01 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
EP4277904A1 (de) 2021-01-15 2023-11-22 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2022170002A1 (en) 2021-02-03 2022-08-11 Seagen Inc. Immunostimulatory compounds and conjugates
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2022251850A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
TW202400137A (zh) 2022-03-17 2024-01-01 美商思進公司 喜樹鹼偶聯物
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
US20240226313A1 (en) 2022-11-17 2024-07-11 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2360794C2 (de) * 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
CH596313A5 (de) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US4898824A (en) * 1986-12-09 1990-02-06 Miles Inc. Crosslinked polyacrylamide-sulfhydryl polymer for immobilization of biologically active substances
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH0796558B2 (ja) * 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co., Wayne Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
AU6048294A (en) * 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors

Also Published As

Publication number Publication date
DK0469074T3 (da) 1996-08-26
JP2557144B2 (ja) 1996-11-27
ATE140969T1 (de) 1996-08-15
DE69027989T2 (de) 1997-02-20
WO1990012874A3 (en) 1991-01-10
AU5553790A (en) 1990-11-16
EP0668353A1 (de) 1995-08-23
EP0469074B1 (de) 1996-07-31
JPH04504801A (ja) 1992-08-27
US5166322A (en) 1992-11-24
ES2090132T3 (es) 1996-10-16
WO1990012874A2 (en) 1990-11-01
EP0469074A1 (de) 1992-02-05
EP0668354A1 (de) 1995-08-23

Similar Documents

Publication Publication Date Title
DE69027989D1 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
EP0458064A3 (en) Stabilization of somatotropins and other proteins by modification of cysteine residues
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
HUT58813A (en) Process for producing tissue-plasminogen activator derivative
AU6444190A (en) A polypeptide
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
GR82243B (de)
DE69525544D1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
DE69029377D1 (de) Substituierungsanaloge von magaininpeptiden
CA2004764A1 (en) Ancrod proteins, their preparation and use
HU911358D0 (en) Grf analogues
ES8204713A1 (es) Un procedimiento para aislar un polipeptido purificado
JPS5551045A (en) Preparation of endorphin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee